Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

2360

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Immunization

Interventions

BIOLOGICAL: PCV21 vaccine
BIOLOGICAL: Prevnar 20 vaccine
BIOLOGICAL: M-M-R II vaccine
BIOLOGICAL: Rotarix
BIOLOGICAL: RotaTeq
BIOLOGICAL: Vaxelis vaccine
BIOLOGICAL: Varivax
BIOLOGICAL: Priorix
BIOLOGICAL: VAQTA
BIOLOGICAL: Havrix

Sponsor

Sanofi